ReviewTurk patoloji dergisi2021
Thyroid Cancer After Chernobyl: Re-Evaluation Needed.
Review in Turk patoloji dergisi, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Thyroid Cancer in Regions Most Contaminated after the Chernobyl Disaster.Journal of biomedical physics & engineering · 2024Article
- Prediction of cytology-histology discrepancy when Bethesda cytology reports benign results for thyroid nodules in women: with special emphasis on pregnancy.The Libyan journal of medicine · 2023Article
- Chernobyl Cancer Studies with Overseas Control: High Grade vs. Late Detection.Turk patoloji dergisi · 2022Article
- Effectiveness and Safety of Levothyroxine Tablets Combined with Iodine-131 in the Treatment of Thyroid Cancer.Journal of oncology · 2022Article
- Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure.Frontiers in pharmacology · 2021Review
- Chernobyl-Related Cancer and Precancerous Lesions: Incidence Increase vs. Late Diagnostics.Dose-response : a publication of International Hormesis Society · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid carcinoma in people exposed to radiation during their childhood and adolescence is the only solid cancer for which the incidence increase as a result of the Chernobyl accident is regarded to be proven. The main evidence in favor of a cause-effect relationship between radiation and thyroid cancer incidence increase comes from epidemiologic studies. Bias in some studies was caused by the screening effect, improved diagnostics after the accident, overdiagnosis, registration of patients from non-contaminated territories as Chernobyl victims, recall bias, dose-dependent selection and self-selection. Prior to the accident, the registered incidence of pediatric thyroid carcinoma was lower in the former Soviet Union than in other industrialized countries i.e. there were undiagnosed cases in the population. The screening found not only small nodules but also late-stage tumors interpreted as radiogenic cancers developing after a short latency. Pediatric thyroid cancers detected during first 10 years after the accident were larger than those detected later on average, many tumors being poorly differentiated and metastatic. The relationship of thyroid cancer and Chernobyl exposures is not denied here; however, it is argued that the quantity of radiogenic cases has been overestimated according to the mechanisms discussed in this paper. In addition, it is suggested that results of some Chernobyl-related molecular-genetic and other studies should be re-evaluated, considering that many tumors detected by the screening or brought from non-contaminated areas and registered as exposed to the fallout were advanced cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.